FDA Authorizes New U...
BD Synapsys™ M...
24th April 2018 Content supplied by: ELITechGroup
ELITechGroup and R-Biopharm Cooperate to Expand Real-Time PCR Portfolio
ELITechGroup, a leading company in sample-to-result molecular diagnostics, and R-Biopharm, a globally active life science company, announced today a worldwide agreement to strengthen their positions in molecular infectious disease testing. Under this agreement, R-Biopharm and ELITechGroup will cooperate in the development, production and marketing of Real-Time PCR reagents.
“We are very pleased to have won R-Biopharm as a partner to expand our molecular diagnostics portfolio.” said Christoph Gauer, CEO of ELITechGroup. “This collaboration will contribute to complete the menu of our sample-to-result system ELITe InGenius®. We will increase the overall number of CE-IVD assays from currently 23 to 33 by the end of 2018 making ELITe InGenius® the system with the broadest CE-IVD menu on the market.”
“Collaborating with ELITechGroup will leverage and strengthen the position of R-Biopharm in the field of Molecular Diagnostics, stated Ralf Dreher, CEO of R-Biopharm. As Molecular Diagnostics is one key pillar within the cross divisional strategy in the R-Biopharm Group, we are confident that this partnership will contribute significantly towards the overall success of the company.”
Date Published: 24th April 2018
Source article link: View
FDA Authorizes New Use of
BD Synapsys™ Microbiology Informatics